Definium (DFTX) CEO Robert Barrow Receives 375,000-Share Award

What Happened

• Robert Barrow, Chief Executive Officer of Definium Therapeutics (DFTX), was granted 375,000 common shares (reported as an award/acquisition) on August 12, 2026. The shares were reported at $0.00 cash paid — this is a performance-based award, not a market purchase or sale.

Key Details

• Transaction date and price: Aug 12, 2026; 375,000 shares at $0.00 (code A — award/grant).
• Shares owned after transaction: Not specified in the filing.
• Footnote (F1): These 375,000 common shares represent the second tranche of performance share units granted effective March 12, 2025. They remain subject to vesting based on Mr. Barrow’s continued employment through March 12, 2028 and are contingent on achieving specified clinical and regulatory milestones under the Performance Share Unit Award Agreement.
• Filing timeliness: Reported on Aug 12, 2026 (same-day report as the transaction date), indicating no late filing noted.

Context

• These are performance share units (contingent awards) rather than an outright purchase or sale. The units convert to common shares only if the company meets the specified milestones and the CEO remains employed through the vesting period. Awards like this are common for aligning executive incentives with long-term company milestones and do not represent immediate cash investment or disposition.